Review anchor
Polyunsaturated fatty acid 5-lipoxygenase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Polyunsaturated fatty acid 5-lipoxygenase
CHEMBL215
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Polyunsaturated fatty acid 5-lipoxygenase as ChEMBL target CHEMBL215, mapped to UniProt P09917. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL215
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P09917
Polyunsaturated fatty acid 5-lipoxygenase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Polyunsaturated fatty acid 5-lipoxygenase matters
Polyunsaturated fatty acid 5-lipoxygenase is reviewed as Polyunsaturated fatty acid 5-lipoxygenase (UniProt P09917); Polyunsaturated fatty acid 5-lipoxygenase shows approved-linked disease relevance led by ulcerative colitis. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 3519 compounds, and 827 assays, with lead potency reaching pChEMBL 9.3.
Protein context
Polyunsaturated fatty acid 5-lipoxygenase
Polyunsaturated fatty acid 5-lipoxygenase Sequence length is 674 aa.
Review this target as Polyunsaturated fatty acid 5-lipoxygenase, mapped to UniProt P09917. Sequence length is 674 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P09917
Protein
Disease context
ulcerative colitis
Polyunsaturated fatty acid 5-lipoxygenase shows approved-linked disease relevance led by ulcerative colitis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BALSALAZIDE DISODIUM, MESALAMINE, OLSALAZINE SODIUM.
Start review with ulcerative colitis because it currently carries approved-linked support. Linked drugs include BALSALAZIDE DISODIUM, MESALAMINE, OLSALAZINE SODIUM, SULFASALAZINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
4 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 7 approved drugs, 3519 compounds, and 827 assays for this target. The dominant activity type is IC50. CHEMBL205800 is the current potency anchor at pChEMBL 9.3.
Use CHEMBL205800 as the tractability anchor when discussing potency (pChEMBL 9.3).
Activity source · ChEMBL 36 via Core Engine
7 approved
pChEMBL 9.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Polyunsaturated fatty acid 5-lipoxygenase matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P09917, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why ulcerative colitis is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3519
Total Compounds
827
Total Assays
7
Approved Drugs
IC50: 4251.0, KI: 13.0, EC50: 62.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL205800
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL377821
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL377094
|
9.1 | IC50 | — |
|
|
No preferred name
CHEMBL204365
|
9.1 | IC50 | — |
|
|
No preferred name
CHEMBL16596
|
8.8 | IC50 | Clinical |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ZILEUTON
CHEMBL93
|
1996 |
Source Header